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Background: Neuromyelitis optica spectrum disorder (NMOSD) can coexist with non-organ-specific or organ-specific
autoimmune diseases. The aim of this study was to investigate and compare the features between NMOSD without
and with autoimmune diseases, and NMOSD with non-organ-specific and organ-specific autoimmune diseases.
Methods: One hundred and fifty five NMOSD patients without autoimmune diseases (n = 115) and with autoimmune
diseases (n = 40) were enrolled. NMOSD with autoimmune diseases were divided by organ-specific autoimmune
diseases. The clinical, laboratory and magnetic resonance imaging features between two groups were assessed.
Results: Motor deficit was less frequent in NMOSD patients with non-organ-specific autoimmune diseases (p = 0.024).
Cerebrospinal fluid white blood cell and protein, serum C-reactive protein and immunoglobulin G were lower in
NMOSD patients without autoimmune diseases, while several autoantibodies seropositivity and thyroid indexes were
significantly higher in NMOSD patients with autoimmune diseases (p < 0.05). No difference was found in other clinical
and laboratory characteristics between different NMOSD subtypes (p > 0.05). NMOSD patients with autoimmune
diseases had higher brain abnormalities than NMOSD without autoimmune diseases (p < 0.001).
Conclusions: The characteristics between NMOSD without and with autoimmune diseases were similar. NMOSD with
autoimmune diseases have high frequency of brain abnormalities.
Keywords: Neuromyelitis optica, Neuromyelitis optica spectrum disorder, Non-organ-specific autoimmune diseases,
Organ-specific autoimmune diseases, Autoantibodies, Magnetic resonance imagingBackground
Neuromyelitis optica (NMO) is a severe demyelinating
disease of the central nervous system that affects the
optic nerve and spinal cord but has protean and diverse
potential clinical and radiological manifestations [1-3].
The broadened array of disorders associated with NMO
immunoglobulin G (IgG) has been termed ‘NMO spectrum
disorders’ (NMOSD), the diagnosis of which is greatly
facilitated by the association of NMOSD with a specific
biomarker for NMO, NMO-IgG [1]. Several groups have
recognized a strong association of NMOSD with non-
organ-specific autoimmune diseases (e.g. systemic lupus
erythematosus (SLE), Sjögren syndrome (SS), rheumatoid* Correspondence: lzqzssy@gmail.com
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unless otherwise stated.arthritis (RA), undifferentiated connective tissue disease
(UCTD)), and organ-specific autoimmune diseases (e.g.
thyroid diseases, myasthenia gravis) [4-6]. However, few
systemic studies have focused on the relationship between
NMOSD without and with autoimmune diseases, and
NMOSD with non-organ-specific and organ-specific auto-
immune diseases. The characteristics of different NMOSDs,
particularly NMOSD with non-organ-specific and organ-
specific autoimmune diseases, were not studied enough.
In this study, we investigated and compared the clinical,
laboratory and magnetic resonance imaging (MRI) features
between NMOSD without and with autoimmune dis-
eases. Furthermore, the characteristics of NMOSD with
non-organ-specific and organ-specific autoimmune diseases
were also investigated.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Patients
Our database comprised 170 Chinese patients with
NMOSD who were diagnosed and admitted from
March 1, 2002 to March 1, 2013 in the MS Center of
the Third Affiliated Hospital of Sun Yat-sen University,
Guangzhou, China. NMO was diagnosed according to
the 2006 Wingerchuk criteria [2]. In addition, NMOSD
was diagnosed according to the 2007 Wingerchuk criteria
[1]. Other included were: (a) all of these patients whose
serum samples were tested for NMO-IgG, autoreactive
antibodies (antinuclear antibodies (ANAs), extractable
nuclear antigen autoantibodies (ENAs), rheumatoid factors
(RFs) anti-neutrophil cytoplasmic antibodies (ANCAs)),
immunoglobulins, complements, thyroid hormones and
autoantibodies; and (b) also MRI of the brain and spinal
cord available for review. Non-organ-specific autoimmune
diseases (e.g. SLE [7], SS [8], RA [9], UCTD [10]), and
organ-specific autoimmune diseases (e.g. thyroid diseases)
were diagnosed by neurologists/rheumatologists/endocri-
nologists according to the criteria and typology guidelines.
Clinical data and MRI scans were collected from these
individuals, a group that including 115 NMOSD patients
without autoimmune diseases and 40 with autoimmune
diseases (20 with non-organ-specific autoimmune diseases
and 18 with organ-specific autoimmune diseases).
This study was approved by the local Ethics Committee
of the Third Affiliated Hospital of Sun Yat-sen University.
Informed consents for this investigation were obtained
from the patients or their family members.
Laboratory testing
Blood and cerebrospinal fluid (CSF) samples were obtained
from all the patients in our study during hospital admission.
All profiling for each patient was performed using commer-
cially clinical laboratory assays. CSF oligoclonal banding
(OCB) and NMO-IgG were tested in our clinical neuroim-
munological Laboratory. Autoreactive antibodies (ANAs,
ENAs, RFs, ANCAs) testing were performed at the
clinical rheumatology immunology laboratory of Sun
Yat-sen University. The immunoglobulins, complements,
thyroid indexes, and other profiling were tested in the
clinical laboratory of Sun Yat-sen University.
Magnetic resonance imaging
Brain and spinal cord MRI scans were performed in all
patients using a GE 1.5 T MR scanner (General Electric,
Milwaukee, Wisconsin, USA). The slice thickness of the
axial scans was 5 mm. Conventional MRI protocols were
used in all patients: T1 with and without gadolinium en-
hancement (400/15.5 ms, TR/TE) and T2 (2500– 3500/
100 ms, TR/TE) for spinal cord MRI; and T1 with and
without gadolinium enhancement (2128–2300/11.6–
12.4 ms, TR/TE), T2 (4600–4640/97.8–102 ms, TR/TE),and fluid-attenuated inversion recovery (FLAIR) (8800/
120 ms, TR/TE) for brain MRI. Each patient underwent
MRI scanning at the time of the initial diagnosis, prior
to corticosteroid treatment. No patients were receiving
immunomodulatory treatment at the time of the MRI
scanning. The numbers, locations, and diameters of
lessions were recorded. All image archives were reviewed
with a DICOM viewer on a Macintosh computer. An
experienced neuroradiologist and a neurologist, both of
whom were blinded to the diagnostic categorization and
the patients’ clinical features, each analyzed all of the MRI
scans. The final assessments were made by consensus.
Statistical analysis
Statistical analysis was performed by SPSS version 22.0.
Values of p = 0.05 were considered statistically significant.
Quantitative data were processed using the Mann–Whitney
U-test or Student’s t-test. All quantitative data in this study
are presented as mean ± standard deviation (SD) or median
(range). Qualitative data were analyzed with the χ2 test
or Fisher’s exact test. Power calculations indicated these
were 80% power to detect 9.7% (n = 155) and 27.6%
(n = 40) differences in the percentage of features, with
alpha set at 0.05.
Results
The data of 170 patients with NMOSD were reviewed
between 2002 and 2013. A total of 155 patients satisfied
the diagnostic criteria for inclusion in this study: 115
NMOSD patients without autoimmune diseases and 40
with autoimmune diseases (22 NMOSD patients with
non-organ-specific autoimmune diseases and 18 NMOSD
patients with organ-specific autoimmune diseases). The
details of the enrollment process can be seen in the
flowchart (Figure 1).
The demographic and clinical features of the patients
are summarized in Table 1. There were no statistical
differences in demographic and clinical characteristics
between NMOSD without and with autoimmune diseases
(p > 0.05). After further analysis, motor deficit was less
frequent in NMOSD patients with non-organ-specific
autoimmune diseases than in NMOSD patients with organ-
specific autoimmune diseases (p = 0.024). No difference was
found in other demographic and clinical features between
NMOSD patients with non-organ-specific autoimmune
diseases and NMOSD patients with organ-specific auto-
immune diseases (p > 0.05).
The laboratory features of the patients are summarized in
Table 2. CSF white blood cell (WBC) and protein were sig-
nificantly lower in NMOSD patients without autoimmune
diseases than in NMOSD patients with autoimmune dis-
eases (p < 0.05), while CSF glucose was significantly higher
in NMOSD patients without autoimmune diseases than in
NMOSD patients with autoimmune diseases (p = 0.012).
Figure 1 Study flowchart. Abbreviations: SLE = systemic lupus erythematosus; SS = Sjögren syndrome; RA = rheumatoid arthritis; UCTD =
undifferentiated connective tissue disease; GD = Graves’ disease.
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http://www.biomedcentral.com/1471-2377/14/162Serum C-reactive protein (CRP) was significantly lower
in NMOSD patients without autoimmune diseases than
NMOSD patients with autoimmune diseases (p = 0.017).
Furthermore, ANA, anti-SSA/Ro antibodies (SSA), anti-
SSB/La antibodies (SSB), anti-double stranded DNA
antibodies (Ds-DNA), anti-nucleosome antibody (AnuA),Table 1 Demographic and clinical characteristics between NM
between NMOSD with non-organ-specific and organ-specific
NMOSD
Without autoimmune
diseases (n = 115)
With autoimmune
diseases (n = 40)
Gender, F: M 91: 24 37: 3
Age, years 37.63 ± 14.33 40.71 ± 13.80
Age at onset, years 34.20 ± 13.70 37.37 ± 13.50
Disease duration, years 1.83 (0.08, 30.00) 1.33 (0.08, 31.08)
Annualized relapse rate 0.66 (0, 12.00) 0.89 (0, 6.00)
EDSS at last visit 2.0 (0, 23.0) 2.5 (0, 10.0)
Clinical features, n (%)
Headache 18 (15.7%) 8 (20.0%)
Nystagmus 6 (5.2%) 4 (10.0%)
IHN 26 (22.6%) 12 (30.0%)
Bulbar paralysis 9 (7.8%) 2 (5.0%)
Bowel or bladder dysfunction 49 (42.6%) 18 (45.0%)
Visual impairment 98 (85.2%) 33 (82.5%)
Motor deficit 68 (59.1%) 21 (52.5%)
Sensory deficit 83 (72.2%) 25 (62.5%)
Neuropathic pain 29 (25.4%) 13 (32.5%)
Abbreviations: EDSS Expanded Disability Status Scale, F: M female: male, IHN intractable
*p < 0.05.anti-Sm antibodies (Sm) seropositivity, and serum IgG
were significantly lower in NMOSD patients without
autoimmune diseases than in NMOSD patients with
autoimmune diseases (p < 0.05), while anti-thyroglobulin
antibodies (TG) seropositivity, thyroxin (T4), and free
thyroxin (FT4) were significantly higher in NMOSDOSD without and with autoimmune diseases, and
autoimmune diseases
NMOSD with autoimmune diseases
P Non-organ-specific (n = 22) Organ-specific (n = 18) P
0.055 22: 0 15: 3 0.165
0.240 40.90 ± 14.86 40.47 ± 12.80 0.924
0.207 36.91 ± 14.63 37.94 ± 12.37 0.814
0.219 1.25 (0.08, 31.08) 2.67 (0.08, 7.00) 0.414
0.183 0.80 (0, 3.43) 0.95 (0, 6.00) 0.784
0.067 2.5 (1.0, 8.5) 3.0 (0, 10.0) 0.529
0.526 3 (13.6%) 5 (27.8%) 0.475
0.289 2 (9.1%) 2 (11.1%) 0.832
0.349 4 (18.2%) 8 (44.4%) 0.071
0.549 1 (4.5%) 1 (5.6%) 1.000
0.793 7 (31.8%) 11 (61.1%) 0.064
0.682 18 (81.8%) 15 (83.3%) 0.900
0.465 8 (36.4%) 13 (72.2%) 0.024*
0.252 14 (63.6%) 11 (61.1%) 0.870
0.388 6 (27.3%) 7 (38.9%) 0.435
hiccup and nausea, NMOSD neuromyelitis optica spectrum disorders.
Table 2 Laboratory features between NMOSD without and with autoimmune diseases, and between NMOSD with
non-organ-specific and organ-specific autoimmune diseases
NMOSD NMOSD with autoimmune diseases
Without autoimmune
diseases (n = 115)
With autoimmune
diseases (n = 40)
P Non-organ-specific (n = 22) Organ-specific (n = 18) P
CSF Index
WBC (106) 6 (0, 140) 10 (0, 48) 0.002* 12 (2, 48) 9.5 (0, 46) 0.307
Protein (g/l) 0.22 (0.06, 1.64) 0.27 (0.12, 0.80) 0.017* 0.27 (0.19, 0.80) 0.32 (0.12, 0.72) 0.754
Glucose (mmol/l) 3.47 ± 0.70 3.11 ± 0.94 0.012* 2.88 ± 0.23 3.41 ± 1.59 0.075
Chloride (mmol/l) 126.3 ± 5.1 126.6 ± 2.8 0.657 126.3 ± 6.9 127.0 ± 9.7 0.434
OCB, n (%) 6 (5.2%) 3 (7.5%) 0.595 2 (9.1%) 1 (5.6%) 1.000
Serums Index
CRP (mg/l) 2.33 ± 4.37 5.63 ± 7.62 0.001* 2.16 (0.00, 26.09) 0.80 (0.10, 15.00) 0.289
ESR (mm/H) 12.90 ± 7.89 14.04 ± 13.39 0.519 10.5 (1.3, 50.0) 7.00 (3.0, 24.0) 0.414
NMO-IgG, n (%) 71 (67.0%) 32 (80.0%) 0.120 18 (81.8%) 14 (77.8%) 0.751
ANA, n (%) 16 (13.9%) 20 (50.0%) <0.001** 18 (81.8%) 2 (11.1%) <0.001**
SSA, n (%) 2 (1.7%) 20 (50.0%) <0.001** 20 (90.9%) 0 (00.0%) <0.001**
SSB, n (%) 1 (0.9%) 11 (27.5%) <0.001** 11 (50.0%) 0 (00.0%) 0.002*
RF, n (%) 2 (1.7%) 3 (7.5%) 0.075 2 (9.10%) 1 (5.60%) 1.000
Ds-DNA, n (%) 0 (0.0%) 5 (12.5%) 0.001* 5 (22.7%) 0 (00.0%) 0.053
AnuA, n (%) 0 (0.0%) 3 (7.5%) 0.021* 3 (13.6%) 0 (00.0%) 0.305
AHA, n (%) 0 (0.0%) 1 (2.5%) 0.579 1 (4.5%) 0 (00.0%) 1.000
RNP, n (%) 0 (0.0%) 2 (5.0%) 0.110 2 (9.1%) 0 (00.0%) 0.492
Sm, n (%) 0 (0.0%) 3 (7.5%) 0.021* 3 (13.6%) 0 (00.0%) 0.305
Jo-1, n (%) 0 (00.0%) 0 (00.0%) - 0 (00.0%) 0 (00.0%) -
Scl-70, n (%) 0 (00.0%) 0 (00.0%) - 0 (00.0%) 0 (00.0%) -
ANCA, n (%) 0 (00.0%) 0 (00.0%) - 0 (00.0%) 0 (00.0%) -
Rib-P, n (%) 0 (0.0%) 2 (5.0%) 0.110 2 (9.1%) 0 (00.0%) 0.492
AKA, n (%) 0 (00.0%) 0 (00.0%) - 0 (00.0%) 0 (00.0%) -
RA33, n (%) 0 (00.0%) 0 (00.0%) - 0 (00.0%) 0 (00.0%) -
CCP, n (%) 0 (00.0%) 0 (00.0%) - 0 (00.0%) 0 (00.0%) -
IgG (g/l) 12.46 ± 4.95 18.33 ± 0.82 <0.001** 14.18 (7.00, 38.80) 12.61 (7.00, 33.22) 0.765
IgA (g/l) 1.41 ± 0.40 1.51 ± 4.95 0.310 1.30 (0.45, 3.60) 1.28 (0.56, 2.15) 0.142
IgM (g/l) 1.15 ± 0.37 1.06 ± 0.38 0.169 1.14 (0.45, 1.75) 0.97 (0.58, 1.99) 0.454
C3 (g/l) 1.09 ± 0.24 1.04 ± 0.39 0.334 1.06 ± 0.17 1.01 ± 0.13 0.667
C4 (g/l) 0.23 ± 0.15 0.19 ± 0.15 0.116 0.15 (0.04, 0.93) 0.15 (0.03, 0.32) 0.935
CH50 (U/ml) 44.11 ± 12.80 39.60 ± 17.12 0.082 41.50 (10.00, 66.00) 33.00 (19.00, 61.00) 0.549
TPO (U/ml) 54.46 ± 72.57 86.02 ± 124.90 0.055 29.3 (5.7, 60.0) 99.9 (11.7, 533.1) 0.019*
TG (U/ml) 42.82 ± 54.46 91.83 ± 127.25 0.001* 34.05(10.11, 97.14) 82.10 (1.99, 500.00) 0.003*
T3 (nmol/l) 1.96 ± 1.60 4.01 ± 13.72 0.114 1.99 (0.66, 2.45) 1.20 (0.70, 88.08) 1.000
T4 (nmol/l) 97.47 ± 25.95 120.95 ± 65.17 0.002* 106.5 (76.9, 170.0) 94.8 (11.7, 363.6) 0.765
FT3 (pmol/l) 4.07 ± 0.97 4.45 ± 3.31 0.273 4.16 (2.59, 5.47) 3.89 (1.03, 23.98) 0.903
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Table 2 Laboratory features between NMOSD without and with autoimmune diseases, and between NMOSD with
non-organ-specific and organ-specific autoimmune diseases (Continued)
FT4 (pmol/l) 15.62 ± 4.67 20.21 ± 15.91 0.006* 17.06 (10.89, 22.92) 17.18 (8.60, 99.25) 0.663
TSH (uIU/ml) 1.91 ± 2.48 2.85 ± 6.05 0.169 1.93 (0.42, 4.02) 0.98 (0.01,36.50) 0.149
Abbreviations: AHA anti-histone antibody, AKA anti-keratin antibodies, ANA antinuclear antibodies, ANCA anti-neutrophil cytoplasmic antibodies, ANuA anti-nucleosome
antibody, C complements, CCP anti-cytosolic carboxypeptidase antibodies, CH50 50% complement hemolysis, CRP C-reactive protein, CSF cerebrospinal fluid, Ds-DNA
anti-double stranded DNA antibodies, ESR erythrocyte sedimentation rate, FT3 free triiodothyronine, FT4 free thyroxin, IgG immunoglobulin G, Jo-1 anti-Jo-1 antibodies,
NMO-IgG neuromyelitis optica immunoglobulin G, NMOSD neuromyelitis optica spectrum disorders, OCB oligoclonal banding, RA33 anti-RA33 antibodies, RF rheumatoid
factor, Rib-P anti-ribosomal P protein antibodies, RNP anti-ribonucleoprotein antibodies, Scl-70 anti-topoisomerase I antibodies, Sm anti-Sm antibodies, SSA Anti-SSA/Ro
antibodies, SSB anti-SSB/La antibodies, T3 triiodothyronine, T4 thyroxine, TG anti-thyroglobulin antibodies, TSH thyroid-stimulating hormone, TPO anti-thyroid peroxidase
antibodies, WBC white blood cell.
**p < 0.001, *p < 0.05.
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IgG was detectable in 67.0% (71/115) NMOSD without
autoimmune diseases and in 80.0% (32/40) NMOSD
patients with autoimmune diseases (p = 0.120).
NMOSD patients with autoimmune diseases were divided
two groups with non-organ-specific and organ-specific auto-
immune diseases. There were no statistical differences in
CSF indexes between two groups (p > 0.05). ANA, SSA,
SSB seropositivity was significantly higher in NMOSD
patients with non-organ-specific autoimmune diseases than
in NMOSD patients with organ-specific autoimmune dis-
eases (p < 0.05), while anti-thyroid peroxidase antibodies
(TPO) and TG seropositivity was significantly lower in
NMOSD patients with non-organ-specific autoimmune
diseases than in NMOSD patients with organ-specific auto-
immune diseases (p < 0.05). NMO-IgG was detectable
in 81.8% (18/22) NMOSD with non-organ-specific auto-
immune diseases, while in 77.8% (14/18) NMOSD patients
with organ-specific autoimmune diseases (p = 0.751). No
difference was found in other autoantibodies, complements,
and thyroid hormones between two groups (p > 0.05).
As shown in Table 3 and Figure 2, NMOSD patients
with autoimmune diseases had higher brain abnormalities
than NMOSD without autoimmune diseases (100.0% vs
67.0%, p < 0.001). However, there was no statistical differ-
ence in other MRI features between two group divided
methods (p > 0.05). Longitudinally extensive transverse
myelitis (LETM) lesions on spinal cord MRI were noted in
70.4% (81/115) NMOSD patients without autoimmune
diseases and in 70.0% (28/40) NMOSD patients with auto-
immune diseases.
Discussion
In the present study, we found that NMOSD with auto-
immune diseases have higher frequency of brain abnormal-
ities than NMOSD without autoimmune diseases. We also
found most clinical, laboratory, and MRI features do not
differ significantly between different NMOSD subtypes
divided by autoimmune diseases, while several CSF indexes,
autoantibodies, and thyroid indexes differ significantly.
Motor deficit is typical feature of NMOSD. Furthermore,
we found motor deficit was less frequency in patients withnon-organ-specific autoimmune diseases. That finding was
consistent with our spinal cord MRI findings that cervical
cord lesions were less prevalent in patients with non-organ-
specific autoimmune diseases, though the difference was
not statistically significant. Intractable hiccup and nausea
(IHN) is rare and unique symptom in NMOSD. Several
studies have reported IHN can be seen in 15.7-62.0% NMO
patients [11,12]. In our case series, 18.2-44.4% patients
had IHN, though the difference was not statistically sig-
nificant. Area postrema and nucleus tractus solitarius
in the dorsomedial medulla and ventrolateral respiratory
center involvement were the reasons for IHN. Previous re-
port had found dorsal and pericanal regions of the me-
dulla oblongata are frequently involved in NMO [13]. One
of the explanations for this regional preference is the rela-
tive abundance of aquaporin-4 (AQP4) expression and
compromised blood–brain barrier functions in these
areas. Though clinical observations strongly suggested
that many patients with NMO have neuropathic pain
(NP), few systemic studies have focused on NP in
NMOSD. Elsone et al. reported 27.3% of NMO showed
neuropathic pruritus, a special NP [14]. However, we de-
scribe the cases of 25.4% and 32.5% with NP in our pa-
tients. Kanamori et al. had found that pain in NMO is
more frequent and severe than in multiple sclerosis [15].
NP may be related to the location of lesions in dorsal horn
of spinal cord or spinal nucleus of trigeminal nerve or
peri-aqueductal pathways [14]. Demographic and clinical
features do not differ significantly between NMOSD
without and with autoimmune diseases in our study.
In the current study, CSF WBC and protein, serum
CRP and IgG were higher in NMOSD patients with
autoimmune diseases. It suggests that the immune status
is more active in patients with autoimmune diseases
than that in patients without autoimmune diseases.
Athough all NMOSD subtypes can found autoantibodies
in the serum (especially ANA, SSA, SSB and RF in our
study), different subtypes should have different autoanti-
bodies seropositivity. These can be partly attributable to
our inclusion criteria to recruit patients with different
autoimmune diseases. In fact, ANAs are common in
patients with NMOSD, especially in NMOSD with SLE/
Table 3 MRI features between NMOSD without and with autoimmune diseases, and between NMOSD with
non-organ-specific and organ-specific autoimmune diseases
NMOSD NMOSD with autoimmune diseases
Without autoimmune
diseases (n = 115)
With autoimmune
diseases (n = 40)
P Non-organ-specific (n = 22) Organ-specific (n = 18) P
Brain lesions, n (%) 77 (67.0%) 40 (100.0%) <0.001** 22 (100.0%) 18 (100.0%) -
Brain lobes 50 (43.5%) 23 (57.5%) 0.126 12 (54.5%) 11 (61.1%) 0.676
Basal ganglia 15 (13.0%) 8 (20.0%) 0.286 6 (27.3%) 2 (11.1%) 0.382
Hypothalamic and thalamic 12 (10.4%) 2 (5.0%) 0.302 1 (4.5%) 1 (5.6%) 1.000
Ventricle and aqueduct 21 (18.3%) 10 (25.0%) 0.359 4 (18.2%) 6 (33.3%) 0.463
Midbrain 5 (4.2%) 2 (5.0%) 0.864 1 (4.5%) 1 (4.5%) 1.000
Pons 14 (12.2%) 9 (22.5%) 0.114 4 (18.2%) 5 (27.8%) 0.732
Medulla oblongata 29 (25.2%) 13 (32.5%) 0.372 5 (22.7%) 8 (44.4%) 0.145
Cerebellum 8 (7.0%) 1 (2.5%) 0.299 1 (4.5%) 0 (00.0%) 1.000
Spinal cord lesions, n (%) 88 (76.5%) 32 (80.0%) 0.650 17 (77.3%) 15 (83.3%) 0.634
Segments lesions 5 (0, 17) 6 (0, 15) 0.486 4 (0, 17) 6.5 (0, 15) 0.603
LETM 81 (70.4%) 28 (70.0%) 0.959 14 (63.6%) 14 (77.8%) 0.332
Cervical cord 74 (64.3%) 27 (67.5%) 0.719 12 (54.5%) 15 (83.3%) 0.053
Thoracic cord 62 (53.9%) 26 (65.0%) 0.223 14 (63.6%) 12 (66.7%) 0.842
Cervical and thoracic cord 48 (41.7%) 23 (57.5%) 0.085 11 (50.0%) 12 (66.7%) 0.289
Abbreviations: LETM longitudinally extensive transverse myelitis, MRI magnetic resonance imaging, NMOSD neuromyelitis optica spectrum disorders.
**p < 0.001.
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variably from 38 to 75%, of which SSA is frequently
detectable in NMO-IgG seropositive patients [4,16]. The
finding was in agreement with our present study. In one
study, autoantibody markers of SS or SLE were found in
47% patients with NMOSD [17]. In addition, recurrent
myelitis and NMO show positivity for SSA, more fre-
quently (77%) than in monophasic disease (33%) [18].
NMO can be associated with autoimmune thyroid dis-
eases, including chronic thyroiditis, Graves’ disease (GD)
or benign thyroid tumours [19]. In the present study, all
organ-specific autoimmune diseases patients were auto-
immune thyroid diseases that might explain why TPO
and TG seropositivity was frequent in that group. Previous
study based on a large Japanese cohort reported auto-
immune thyroid diseases were seen in 13.6% NMOSD
and were more often observed in the brain-dominant
phenotype (40.0%) [5]. The serum autoantibody NMO-IgG
is a sensitive and specific marker for NMO. Its antigen
is AQP4, the predominant water channel protein in the
central nervous system [20]. Lennon and co-workers
reported the presence of NMO-IgG was 91-100% sero-
positivity for NMO patients [20]. The autoantibody
NMO-IgG is detectable also in patients with recurrent
optic neuritis without myelitis and in a high proportion
of patients with a single episode or recurrence of LETM
without optic neuritis (NMOSD) [17]. NMO-IgG was
detectable in 74-85% samples from patients with NMOSD
[21,22]. In our case series, 67.0-81.8% patients hadNMO-IgG seropositivity, though the difference was not
statistically significant. The reason why NMO-IgG positive
in NMO/LETM frequently associated with autoimmune
diseases is unclear. It has been speculated that the coexist-
ence of the two disorders in the same patient might reflect
a general autoimmune predisposition [23].
The frequency of brain MRI abnormalities is 50–85% in
patients with NMO/NMOSD [24-28]. However, previous
small study had reported all SS patients with NMOSD
had several common brain abnormalities [29]. In present
study, we found brain abnormalities in NMOSD with
autoimmune diseases were more frequent than that in
other NMOSD phenotypes. Among the brain lesions,
asymptomatic lesions are more common; however,
symptomatic brain involvement is also common [30].
Diencephalic or brainstem lesions adjacent to the third
and fourth ventricles, longitudinal lesions of the internal
capsule, and large extensive lesions have been suggested
as characteristic lesions in NMO, even though they are
not commonly observed [13,24,31]. Among the brain
lesions, nonspecific lesions are very commonly found.
They can be dot-like or patchy, < 3 cm in diameter, and
located in the cerebral deep white matter, brainstem, or
cerebellum [30]. The distribution of NMO-characteristic
brain lesions corresponded to sites of high AQP4 expres-
sion, adjacent to the ventricular system at any level [13].
However, other NMO-characteristic brain lesions involved
where AQP4 expression is not particularly high have also
been reported [27,30]. In our case series, patients had a
Figure 2 Representative magnetic resonance imaging (MRI) abnormalities (arrows) in NMOSD patients with autoimmune diseases.
(A) Bilateral thalamic lesions; (B) Bilateral hypothalamus lesions; (C) Basal ganglia lesion; (D) Hypothalamus and periventricular lesions; (E) Aqueduct of
the midbrain lesion; (F) Cervico-medullary lesion; (G) Pons lesion; (H) Cerebellum lesion; (I) Longitudinally extensive transverse myelitis (LETM) lesions.
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midbrain and pons lesions. The result was consistent with
our previous report showing that the medulla was the
most common brainstem lesion location in NMO [32].
MRI of the spine cord has been regarded as the most use-
ful diagnostic test in patients with suspected NMO [33].
The combination of NMO-IgG and a longitudinally exten-
sive (three or more vertebral segments) cord lesion has
been shown to be highly specific for the diagnosis [2].
Lesions are typically located in the cervical or thoracic
cord with central or holocord involvement [34]. In our
case series, although the difference was not statistically
significant between groups, over 60% NMOSD patients
had LETM lesions on spine cord MRI.
Our study has some limitations. First, the number of
NMOSD patients with autoimmune diseases included in
our study is not sufficient. Second, the titer of NMO-IgG
and autoantibodies was not tested, which result couldstrengthen our findings. Third, as a retrospective study,
bias is inevitable. Furthermore, because the patients came
from a single center, we were not able to validate our
findings by applying them to a set of patients from other
hospital. The p-values we reported were not corrected for
multiple hypothesis testing. After post hoc analyses
with Benjamini-Hochberg method, there were no statis-
tical differences in CSF protein and glucose, AnuA and
Sm seropositivity between NMOSD without and with
autoimmune diseases. No difference was found in motor
deficit and TPO between NMOSD with non-organ-specific
and organ-specific autoimmune diseases.
Conclusions
In conclusion, the clinical, laboratory, and MRI features
were similar between different NMOSD subtypes. NMOSD
with autoimmune diseases have high frequency of brain
abnormalities.
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